keyword
MENU ▼
Read by QxMD icon Read
search

eviplera

keyword
https://www.readbyqxmd.com/read/25397539/lipid-changes-in-hiv-patients-switching-to-the-coformulated-single-tablet-ftc-rpv-tdf-eviplera%C3%A2-efficacy-and-safety-analysis-gesida-study-8114
#1
Isabel A Pérez-Hernández, Rosario Palacios, Marisa Mayorga, Carmen M González-Doménech, Manuel Castaño, Antonio Rivero, Alfonso Del Arco, Fernando Lozano, Jesús Santos
INTRODUCTION: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1). Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control (2). The aim of this study was to analyze lipid changes in HIV-patients at 24 weeks after switching to Eviplera® (emtricitabine/RPV/tenofovir disoproxil fumarate [FTC/RPV/TDF]). MATERIALS AND METHODS: Retrospective, multicentre study of a cohort of asymptomatic HIV-patients who switched from a regimen based on 2 nucleoside reverse transcriptase inhibitors (NRTI)+protease inhibitor (PI)/non nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir boosted PI monotherapy to Eviplera® during February-December, 2013; all had undetectable HIV viral load for ≥3 months prior to switching...
2014: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/25397519/determinants-of-use-of-the-fixed-dose-combination-emtricitabine-rilpivirine-tenofovir-eviplera-in-hiv-infected-persons-receiving-care-in-italy
#2
Alessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, Andrea Antinori, Adriana Ammassari, Giulia Marchetti, Claudio Mastroianni, Andrea Gori, Giovanni Di Perri, Gioacchino Angarano, Alessia Carbone, Antonella d'Arminio Monforte
INTRODUCTION: Emtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is licensed in Europe for use only in ARV-naïve patients with a viral load (VL) ≤100,000 copies/mL. OBJECTIVE: To identify factors that may be associated with the use of EVP as first-line regimen in HIV-infected individuals starting cART from ARV-naïve in Italy...
2014: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/25397477/failure-of-daily-tenofovir-to-prevent-hiv-transmission-or-the-establishment-of-a-significant-viral-reservoir-despite-continued-antiretroviral-therapy
#3
Olubanke Davies, Hannah Alexander, Nicola Robinson, Matthew Pace, Michael Brady, John Frater, Julie Fox
INTRODUCTION: Truvada is licenced for HIV-1 prevention in the USA and is available in the private sector. Tenofovir performed as well as Truvada in the PARTNERS PrEP study and is used as HIV pre-exposure prophylaxis (PreP) in some settings. The clinical efficacy of Tenofovir for PrEP outside a clinical trial is unknown. Antiretroviral therapy (ART) at acute HIV-1 infection (AHI) limits the size of the reservoir, optimizing the chance of maintaining viral control off therapy. As such ART at acute HIV infection is proposed to offer a functional cure in a minority of subjects...
2014: Journal of the International AIDS Society
https://www.readbyqxmd.com/read/25352394/emtricitabine-rilpivirine-tenofovir-disoproxil-fumarate-single-tablet-regimen-a-review-of-its-use-in-hiv-infection
#4
REVIEW
Emma D Deeks
The nucleos(t)ide reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF), and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, are now available as a fixed-dose single-tablet regimen (emtricitabine/rilpivirine/tenofovir DF; Complera(®), Eviplera(®)) for the treatment of adults infected with HIV-1. In treatment-naïve adults, once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF with regard to establishing virological suppression over 96 weeks of therapy in a randomized, open-label, phase IIIb study (STaR)...
November 2014: Drugs
https://www.readbyqxmd.com/read/24308712/rilpivirine-drug-profile-of-a-second-generation-non-nucleoside-reverse-transcriptase-hiv-inhibitor
#5
REVIEW
Diego Ripamonti, Enrico Bombana, Marco Rizzi
Rilpivirine (RPV) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family. RPV can be given once daily, is well absorbed and should be administered with food. It is eliminated mainly by hepatic metabolism. Two phase III noninferiority trials (ECHO and THRIVE), compared RPV 25mg with efavirenz (EFV) 600 mg, both given once daily, and combined with 2NRTI backbone. At week 48, response rate for pooled data were 84 versus 82% (difference: 2%; 95% CI: -2.0 to 6...
January 2014: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/23814462/triple-combination-rilpivirine-emtricitabine-and-tenofovir-complera%C3%A2-eviplera%C3%A2-in-the-treatment-of-hiv-infection
#6
Claudia Bernardini, Franco Maggiolo
The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a once-daily, single-tablet regimen (STR) containing one nonnucleoside reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food and Drug Association, European Medicines Agency) in all countries in which it is manufactured, except Switzerland, as first-line highly active antiretroviral therapy (HAART) for the treatment of naïve patients with HIV infection and a viral load HIV-RNA level of ≤100,000 copies/mL...
2013: Patient Preference and Adherence
https://www.readbyqxmd.com/read/23681436/clinical-perspective-on-drug-drug-interactions-with-the-non-nucleoside-reverse-transcriptase-inhibitor-rilpivirine
#7
REVIEW
Herta Crauwels, Rolf P G van Heeswijk, Marita Stevens, Annemie Buelens, Simon Vanveggel, Katia Boven, Richard Hoetelmans
Rilpivirine (TMC278) is a non-nucleoside reverse transcriptase inhibitor approved in combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-naive adults (Edurant(®) 25 mg once daily; Complera(®) [USA]/Eviplera(®) [EU] once daily single-tablet regimen). Rilpivirine should be administered with a meal to optimize bioavailability. Its solubility is pH dependent. Rilpivirine is primarily excreted via the feces with negligible renal elimination. Rilpivirine is predominantly metabolized by cytochrome P450 3A4...
April 2013: AIDS Reviews
https://www.readbyqxmd.com/read/22921088/emtricitabine-rilpivirine-tenofovir-disoproxil-fumarate-single-tablet-regimen-a-guide-to-its-use-in-hiv-1-infection
#8
Katherine A Lyseng-Williamson, Lesley J Scott
The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Eviplera™ [EU]; Complera™ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient population, rilpivirine plus emtricitabine/tenofovir disoproxil fumarate was noninferior to efavirenz plus emtricitabine/tenofovir disoproxil fumarate in terms of reducing viral HIV-1 RNA level to <50 copies/mL and was generally better tolerated than efavirenz plus emtricitabine/tenofovir disoproxil fumarate...
October 1, 2012: Clinical Drug Investigation
https://www.readbyqxmd.com/read/22504027/where-rilpivirine-meets-with-tenofovir-the-start-of-a-new-anti-hiv-drug-combination-era
#9
REVIEW
Erik De Clercq
The triple-drug once-daily combination pill containing tenofovir, emtricitabine and rilpivirine for HIV treatment was launched in 2011, both in the USA (Complera) and the E.U. (Eviplera). The active ingredients of Complera or Eviplera are the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir, the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine, and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. Rilpivirine originated from a collaborative research I had started with Dr...
August 1, 2012: Biochemical Pharmacology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"